Harrow, Inc. Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Harrow, Inc. stock issued during period, value, other for the quarter ending 2025-12-31 was $5.18M.
- Harrow, Inc. stock issued during period, value, other for the quarter ending 2025-09-30 was $7.09M, a 488.46% increase year-over-year.
- Harrow, Inc. stock issued during period, value, other for the quarter ending 2025-06-30 was $12.77M, a 451.82% increase year-over-year.
- Harrow, Inc. stock issued during period, value, other for the quarter ending 2025-03-31 was $0.00.
- Harrow, Inc. stock issued during period, value, other for fiscal 2025 was $25.04M, a 959.95% increase from fiscal 2024.
- Harrow, Inc. stock issued during period, value, other for fiscal 2024 was $2.36M, a 81.85% decline from fiscal 2023.
- Harrow, Inc. stock issued during period, value, other for fiscal 2023 was $13.01M.
- Harrow, Inc. stock issued during period, value, other for fiscal 2022 was -$876.00K.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2025-12-31 | $5.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $25.04M 10-K · filed 2026-03-02 |
| 2025-09-30 | $7.09M 10-Q · filed 2025-11-10 | $19.86M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $12.77M 10-Q · filed 2025-08-11 | $13.97M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-03-02 | $3.52M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.36M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.21M 10-Q · filed 2025-11-10 | $28.35M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $15.87M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$1.16M 10-Q · filed 2025-05-08 | $12.71M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $25.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $13.01M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$11.27M 10-Q · filed 2024-11-14 | -$12.97M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$848.00K 10-Q · filed 2024-08-07 | -$1.70M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$850.00K 10-Q · filed 2024-05-13 | -$949.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$876.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$876.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$99.00K 10-Q · filed 2023-08-09 | -$876.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$777.00K 10-Q · filed 2023-05-11 | -$3.95M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$3.23M 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2021-06-30 | -$3.17M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | -$57.00K 10-Q · filed 2022-05-05 | |
| 2018-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $642.00K 10-K · filed 2020-03-13 |
| 2018-09-30 | $1.00K 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $519.00K 10-Q · filed 2019-08-14 | |
| 2018-03-31 | $122.00K 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $1.12M 10-K · filed 2019-03-12 | |
| 2016-12-31 | $212.00K 10-K · filed 2018-03-08 | |
| 2015-12-31 | $404.00K 10-K · filed 2017-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |